Acute promyelocytic leukemia
MONDO:0012883An aggressive form of acute myeloid leukemia (AML), characterized by arrest of leukocyte differentiation at the promyelocyte stage, due to a specific chromosomal translocation t(15;17) in myeloid cells. APL manifests with easy bruising, hemorrhagic diathesis and fatigue.
Also known as: AML M3, AML with t(15;17)(q22;q12), AML with t(15;17)(q22;q12);(PML/RARalpha) and variants, APL, APML, APML - acute promyelocytic leukaemia, APML - acute promyelocytic leukemia, FAB M3
3109 clinical trials for this condition and its sub-types, 20 tagged with Acute promyelocytic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a Gene-Targeting drug boost chemo for older leukemia patients?
Disease control CompletedThis study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…
Phase 3 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Drug duo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis phase II trial tested two drugs—sirolimus and azacitidine—in 57 people with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that had come back or didn't respond to standard treatment. The goal was to see if the combination could shrink or control the…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could an arsenic drink replace IV drips for leukemia patients?
Disease control CompletedThis study tested an oral liquid form of arsenic trioxide (SDK001) in 12 people with acute promyelocytic leukemia (APL). Researchers compared how well the body absorbs the oral drug versus the standard IV version, and whether food or calcium supplements change absorption. The goa…
Phase 1 • Sponsor: SDK Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Leukemia treatment showdown: which works best?
Knowledge-focused CompletedThis registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes…
Sponsor: Groupe Francophone des Myelodysplasies • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
AI boosts cancer diagnosis speed in small study
Knowledge-focused CompletedThis study tested whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Ten doctors reviewed bone marrow samples with and without AI assistance. The goal was to see if AI improves …
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC